NIKKEI 225
39,206.64 -460.43 (-1.16%) HANG SENG
17,805.08 -284.85 (-1.57%) CRUDE OIL
80.53 -0.37 (-0.46%) GOLD FUTURES
2,309.30 -3.90 (-0.17%) DOW
39,127.80 +15.64 (+0.04%) Bitcoin GBP
48,231.55 -1,122.03 (-2.27%)
QURE Jan 2026 7.000 call
| Previous close | 1.9800 |
| Open | 1.9800 |
| Bid | 0.0000 |
| Ask | 5.0000 |
| Strike | 7.00 |
| Expiry date | 2026-01-16 |
| Day's range | 1.9800 - 1.9800 |
| Contract range | N/A |
| Volume | |
| Open interest | 124 |
GlobeNewswireuniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington’s Disease
~ Designation based on 24-month interim Phase I/II clinical data for AMT-130 announced in December 2023 ~ ~ AMT-130 is the first therapeutic candidate to receive RMAT Designation for Huntington’s disease ~ ~ Receiving RMAT designation enables increased collaboration with the FDA on regulatory approval planning, in addition to the opportunity for expedited product development ~ LEXINGTON, Mass. and AMSTERDAM, June 03, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy co
Simply Wall St.uniQure First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
uniQure ( NASDAQ:QURE ) First Quarter 2024 Results Key Financial Results Revenue: US$8.49m (up 59% from 1Q 2023). Net...
- GlobeNewswire
uniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress
~ On track to initiate FDA interaction regarding AMT-130 in second quarter of 2024 and provide a clinical update from the Phase I/II trials in mid-2024 ~ ~ Clinical trial initiation for Fabry disease on track to begin in second quarter of 2024, followed by refractory mesial temporal lobe epilepsy and SOD1-ALS in third quarter of 2024 ~ ~ Comprehensive review of operations and options to reduce expenses underway and expected to be completed in mid-2024 ~ LEXINGTON, Mass. and AMSTERDAM, May 07, 20
